Skip to main content

Market Overview

Milestone Scientific's Epidural, Intra-Articular Unit Reports Successful Interim Analysis of Trials for Epidural Instrument


Milestone Scientific Inc .'s (NYSE: MLSS) Epidural & Intra-Articular (IA) Subsidiary today announced successful results of the interim analysis of the COMPASS Study (CompuFlo® Assessment Study), a randomized, controlled, parallel group, multicenter, pivotal study to assess the safety and effectiveness of the epidural space verification with the CompuFlo® Epidural Computer Controlled System.

Milestone Scientific's Epidural & IA Subsidiary further announced the clinical trial for the epidural instrument has reached an enrollment of 200 patients. The goal of the pivotal IDE clinical trial is to demonstrate the accuracy of the CompuFlo technology in identifying and confirming the epidural space location.

Leonard Osser, Chief Executive Officer of Milestone Scientific, stated, "The interim analysis of the COMPASS Study clearly achieved the goal set by the FDA IDE Investigational Plan. We look forward to expeditiously continuing our enrollment and completing our trial later this year."

"With the U.S. epidural market estimated at over $7 billion annually and over 2.4 million women receiving epidurals, we believe this instrument will help reduce health risks to patients and malpractice risk to medical professionals administering epidurals," concluded Mr. Osser.


Related Articles (MLSS)

View Comments and Join the Discussion!

Posted-In: News Press Releases

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at